Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Gere diZerega

Chief Medical Officer

NanOlogy

Gere serves as Vice President of Clinical Affairs and Medical Director for NanOlogy. Gere is also CEO and Chairman of US Biotest, and played a key role in establishing the partnership with CritiTech and DFB to form NanOlogy. He, and his team at US Biotest, are responsible for regulatory affairs, clinical trial design, and oversight of clinical trials for all of NanOlogy’s programs.

Gere’s aptitude for drug development was demonstrated while a professor at the University of Southern California, where his research received funding from the NIH, Department of Defense, National Science Foundation, and BARDA. This work led to the elucidation of the renin-angiotensin system in epithelial tissue repair and preovulatory follicle development in the ovary. Projects initiated at the discovery level in Gere’s laboratory at USC were advanced to US Biotest, a drug development company he founded to support regulatory activities and perform clinical trials.

Gere has since contributed to development and regulatory approval of many products sold worldwide, and has collaborated with several “big pharma” companies in creating successful products. He has been recognized for this work by many professional societies in the United States and around the world.

Gere graduated from the University of Kansas, majoring in comparative physiology and cell biology. He received his MD from Baylor College of Medicine, completed his residency at Keck School of Medicine, University of Southern California-Los Angeles County Medical Center, and completed his fellowship at NIH and Walter Reed Army Medical Hospital.

This speaker's sessions:

Back